<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05089838</url>
  </required_header>
  <id_info>
    <org_study_id>2020PHD014-001</org_study_id>
    <nct_id>NCT05089838</nct_id>
  </id_info>
  <brief_title>CMV-TCR-T Cells for Refractory CMV Infection After HSCT</brief_title>
  <official_title>A Study of CMV-TCR-T Cells in the Treatment of Refractory CMV Viremia After HSCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiao-Jun Huang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single centre, single arm, open-label, phase I study to evaluate the safety and&#xD;
      effectiveness of CMV-TCR-T cell immunotherapy in treating refractory CMV infection after&#xD;
      HSCT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CMV infection is a major and potentially life-threatening complication after allogenic&#xD;
      hematopoietic stem cell transplantation (allo-SCT). Pharmacotherapy with ganciclovir and&#xD;
      foscarnet remains the mainstay of treatment and has significantly improve clinical results,&#xD;
      however, it is unsatisfactory owing to toxicity, limited efficacy and risk of developing&#xD;
      resistance.&#xD;
&#xD;
      In recent years, adoptive T cell therapy has been proposed as an alternative option for CMV&#xD;
      infection after allo-SCT. However, patients with transplants from CMV-negative donors are at&#xD;
      highest risk, and an adoptive therapy is missing because CMV-specific T cells are not&#xD;
      available.&#xD;
&#xD;
      CMV TCR-transduced donor-derived T Cells (CMV-TCR-T cells) is an attractive strategy to&#xD;
      specifically redirect T-cell immunity toward CMV. In this prospective clinical phase I trial,&#xD;
      we propose to evaluate the safety and efficacy of stem cell donor-derived CMV-TCR-T cells for&#xD;
      patients with refractory CMV infection after allo-SCT. Donor derived&#xD;
      CMV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of&#xD;
      0.3-1×10E7CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be&#xD;
      monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of participants with adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of CMV-DNA copies</measure>
    <time_frame>3 months</time_frame>
    <description>Changes of CMV-DNA copies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMV-specific immunity reconstitution</measure>
    <time_frame>3 months</time_frame>
    <description>In vivo persistence of the infused CMV-TCR-T cells and reconstitution of CMV-specific immunity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Allogeneic Hematopoietic Stem Cell Transplantation</condition>
  <condition>CMV Infection</condition>
  <arm_group>
    <arm_group_label>CMV-TCR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who enrolled will receive one dose of CMV-TCR-T cells. The dosage ranges from 0.3×10^6 to 1×10^7 TCR+T/Kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CMV-TCR-T cells</intervention_name>
    <description>Patients who developed refractory CMV infection after allo-HSCT will be enrolled, and donor derived CMV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.3-1×10E7CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).</description>
    <arm_group_label>CMV-TCR-T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with acute leukemia (AL) or myelodysplastic syndrome (MDS) who receive&#xD;
             haploid allogeneic hematopoietic stem cell transplantation, pre-transplantation&#xD;
             assessment ≤CR2;&#xD;
&#xD;
          2. Age 18-60, including boundary value, gender unlimited;&#xD;
&#xD;
          3. Refractory CMV infection occurred in the early stage of transplantation : After 2&#xD;
             weeks of standard antiviral treatment, the CMV DNA copy number continued to be ≥1000&#xD;
             copies/mL, and the CMV DNA copy number at the beginning of the treatment decreased by&#xD;
             &lt;log10 ；&#xD;
&#xD;
          4. The transplant donor's HLA-A matching is one of 2402, 0201 or 1101, and the physical&#xD;
             examination is qualified;&#xD;
&#xD;
          5. ECOG ≤ 3, estimated life expectancy&gt; 3 months;&#xD;
&#xD;
          6. Patients who voluntarily sign informed consent and are willing to comply with&#xD;
             treatment plans, visit arrangements, laboratory tests and other research procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with active aGVHD III-IV and / or mild and severe cGVHD;&#xD;
&#xD;
          2. Have received cell therapy such as DLI, CTL, CAR-T, NK or participated in any other&#xD;
             clinical research on drugs and medical devices;&#xD;
&#xD;
          3. Patients who have developed CMV disease;&#xD;
&#xD;
          4. patients with organ failure:&#xD;
&#xD;
               -  Heart: NYHA heart function grade IV;&#xD;
&#xD;
               -  Liver: Grade C that achieves Child-Turcotte liver function grading;&#xD;
&#xD;
               -  Kidney: kidney failure and uremia;&#xD;
&#xD;
               -  Lung: symptoms of respiratory failure;&#xD;
&#xD;
               -  Brain: a person with a disability;&#xD;
&#xD;
          5. Pregnant or lactating women;&#xD;
&#xD;
          6. The researchers found that it was unsuitable for the recipients to be enrolled.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lanping Xu, PhD,MD</last_name>
    <role>Study Chair</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lanping Xu, PhD,MD</last_name>
    <phone>86-010-88324671</phone>
    <email>lpxu_0415@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xuying Pei, PhD</last_name>
    <phone>86-010-88324671</phone>
    <email>peixuying08@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Institute of Hematology,People's hospital Peking University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lanping Xu, Prof.</last_name>
      <phone>8613641028627</phone>
      <email>lpxu_0415@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Yanru Ma</last_name>
      <phone>8613641134402</phone>
      <email>lpxu_0415@vip.sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Xiao-Jun Huang</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

